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RESEARCH ETHICS IN 
DEVELOPING COUNTRIES 
 
The UK funds an increasing amount of biomedical 
research in developing countries. Research proposals 
are reviewed by research ethics committees, usually in 
both the UK and the countries where research is to take 
place. Exact ethical requirements vary according to 
national policy, funding body and research institution. A 
key international document on research ethics, the 
Declaration of Helsinki, will be revised in 2008. This 
POSTnote describes the types of research conducted in 
developing countries, the ethical review process and the 
arising issues. 
Background 
Biomedical research seeks mainly to develop new drugs, 
vaccines and medical techniques and to improve public 
health systems. It often involves human participants, as 
in genetic sampling or clinical trials. In developing 
countries, where infectious diseases cause half of all 
deaths,1 biomedical research targets include HIV/AIDS, 
tuberculosis, malaria and diseases that have received 
limited attention in the past, like sleeping sickness and 
dengue fever.2 UK funding for this research comes from 
three main streams (see Box 1): 
• public sources, including the Department for 
International Development (DFID) and the Medical 
Research Council (MRC); 
• medical charities, such as the Wellcome Trust; 
• private sector pharmaceutical companies. 
 
Ethical review policies and procedures 
There are numerous international and national guidelines 
(see Box 2) on research ethics. Many consider the World 
Medical Association’s (WMA) Declaration of Helsinki to 
be the most influential.3 According to the Declaration and 
other documents, all medical research projects involving 
human subjects should undergo ethical review. This is  
Box 1. Examples of UK-sponsored research 
Department for International Development (DFID) 
DFID contributes to a variety of programmes. These include 
several product development public-private partnerships: the 
International Aids Vaccine Initiative (£20m, 2005-08), the 
International Partnership for Microbicides (£8.7m, 2005-
08), the TB Alliance (£6.5m, 2005-08), the Medicines for 
Malaria Venture (£10m, 2005-10) and the Drugs for 
Neglected Diseases Initiative (£6.5m, 2005-08). 
Medical Research Council (MRC) 
The MRC Laboratories, in The Gambia are the UK’s largest 
single investment in medical research in a developing 
country (£41.6m, 2006-11). Staff work on HIV/AIDS, 
tuberculosis, malaria and other tropical diseases. A second 
research unit in Uganda is based at the Uganda Virus 
Research Institute and focuses on HIV/AIDS (£15.3m, 
2006-2011). 
The Wellcome Trust 
The Trust funds major research programmes in South-east 
Asia, Kenya, Malawi and South Africa, focusing on diseases 
such as dengue, typhoid, HIV/AIDS, tuberculosis and 
malaria, (total funding in developing countries: £203.5m, 
2003-2007). 
Private sector 
Pharmaceutical companies such as GlaxoSmithKline4 and 
Pfizer5 support public-private partnerships working on drug 
discovery for HIV/AIDS, tuberculosis, malaria and previously 
neglected diseases, through research, funding, training and 
sharing medicinal compounds. 
usually carried out by an institutional or independent 
local research ethics committee (REC) or by a national 
ethics committee. A REC will generally expect a research 
proposal to demonstrate: 
• how informed consent (see later sections) will be 
obtained from all research participants; 
• that confidentiality will be ensured; 
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• that potential harm to participants will be minimised;  
• the scientific validity of the project (sometimes also 
assessed by a separate committee). 
Box 2. Research ethics regulation and policies 
Numerous legislative and guidance documents on research 
ethics exist, at international, national and institutional levels. 
Legislation 
Legislation affecting researchers in the UK includes the EU 
Clinical Trials and Good Clinical Practice Directives (2001 
and 2005) and the UK Medicines for Human Use (Clinical 
Trials) Regulations (2004, amended 2006). 
International guidance 
Documents include the World Medical Association’s 
Declaration of Helsinki (2000), which sets out ethical 
principles, as well as regulatory instruments such as the 
Good Clinical Practice guidelines of the World Health 
Organisation (1995) and the International Conference on 
Harmonisation (1996). The Council for International 
Organisations of Medical Sciences has produced guidelines 
outlining how the Helsinki declaration can be applied in 
developing countries. The United Nations Educational, 
Scientific and Cultural Organisation adopted the Universal 
Declaration on Bioethics and Human Rights in 2005, to 
assist member states in the formulation of national 
legislation, regulations or policies. 
National guidance 
The Medical Research Council and the Wellcome Trust in 
the UK have each produced ethical guidelines on research in 
developing countries. The Nuffield Council on Bioethics’ 
report, The Ethics of Research Related to Healthcare in 
Developing Countries (2002, followed up in 2005), is also 
frequently referred to by researchers and RECs in the UK 
and in many other countries. Several institutions in 
developing countries have also produced ethics documents, 
including the Indian Council of Medical Research and the 
Kenyan National Council for Science and Technology. 
For research in the developing world there are further 
considerations. These include: which legislation or 
guidance should be followed; whether RECs have 
sufficient capacity and expertise; how informed consent 
can be obtained; and how projects will relate to and 
meet participants’ needs. 
Policy context 
UK and EU regulations 
The UK’s Medicines for Human Use (Clinical Trials) 
Amendment Regulations (2006) specify that clinical 
trials must be conducted in accordance with the WMA 
Declaration of Helsinki and the EU Directives on Clinical 
Trials and Good Clinical Practice. Several stakeholders 
have sought guidance on whether these requirements 
apply to trials sponsored by or conducted through UK-
based funders, pharmaceutical companies and 
institutions but that take place in developing countries.  
Some interpret them as clearly applying only to trials 
carried out partly or wholly within the EU. Others would 
like further clarification on this issue. 
 
The Declaration of Helsinki was last revised in 2000, but 
the Medicines for Human Use Regulations cite the 1996 
version. In 2008 the Declaration is being revised again. 
The UK’s input into the revision process is being co-
ordinated by the British Medical Association. A collective 
response to the first draft, from bodies such as the 
Department of Health, the MRC, the Nuffield Council on 
Bioethics and the Wellcome Trust, was sent to the WMA 
in early 2008. One concern is that the WMA appears to 
be seeking to expand the scope of the Declaration. A 
second draft will be released for further comment in May 
2008 and the final version will be adopted in October 
2008. The likely impacts of any revisions are as yet 
unknown, as it uncertain whether other international and 
national documents that draw on the Declaration will 
follow suit. 
 
Multiple sources of guidance 
Research ethics guidelines operate at international, 
national and institutional levels (Box 2). Opinions differ 
on how far this proliferation6 of documentation is a 
problem. Some ethicists and researchers appreciate 
being able to draw on different perspectives on how to 
deal with the issues outlined below. They consider a ‘one 
size fits all’ approach inappropriate, as research is carried 
out in different social, cultural and economic contexts. 
Others find the range of guidance confusing, particularly 
on the ‘standard of care’ debate (see Box 3). They would 
prefer the different sources to be streamlined both 
nationally and internationally. Oxfam advocates the 
World Health Organisation’s Good Clinical Practice 
guidelines as a viable universal standard. 
Box 3. The ‘standard of care’ debate 
Standard of care refers to the nature of care and treatment 
provided for research participants.7 The Declaration of 
Helsinki (2000) states that new interventions should be 
tested against the ‘best current’ preventative, diagnostic or 
therapeutic methods. This is sometimes interpreted as 
requiring a ‘universal standard of care’: the best current 
treatment available anywhere in the world. The results of a 
clinical trial testing a new intervention against this standard 
would be of little relevance in countries where such 
treatments are usually unavailable. Hence many researchers, 
ethicists and pharmaceutical companies endorse the best 
treatment available nationally as a minimum standard of 
care, seeing a universal standard as liable to preclude 
important research. The Council for International 
Organisations of Medical Sciences accepts that the best 
current intervention may not be available locally and permits 
an ‘established effective intervention’ to be used instead. 
Ethical review 
Most guidelines require that ethical review should be 
carried out in the country where the research is to take 
place. Where research is conducted in collaboration with 
a UK institution (as is mandatory for MRC-funded 
research overseas, for example), review by a UK-based 
REC is also usually required. For multinational research 
projects this may involve several different ethics 
applications. The various RECs involved may hold 
contrasting views on whether or not a project can be 
approved, particularly if working to differently nuanced 
guidelines. The Nuffield Council on Bioethics advises that 
such disagreements should be avoided or resolved 
through dialogue.7 This rarely takes place, however, so 
that researchers find themselves going back and forth 
between committees, often over relatively small issues. 
Some ethicists see this as a missed opportunity for an 
educational exchange of views between members of 
RECs working in widely varied contexts. 
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Developing local ethical review capacity 
Developing countries vary considerably in their abilities to 
carry out ethical review of biomedical research. Some 
have longstanding systems in place, while others are only 
now beginning to establish them. MalariaGEN (see Box 
4), a large multinational research network, found that it 
needed to engage actively with some RECs in Africa and 
Asia to ensure appropriate review procedures. Some of 
the problems RECs might face include:8 
• heavy workloads, where there are too few RECs to 
deal with growing numbers of research projects; 
• recruiting sufficiently diverse memberships (RECs are 
generally expected to include scientists, ethicists and 
lay persons from different backgrounds and genders); 
• ensuring decisions are made independently of 
governmental, institutional and financial interests; 
• making decisions on new, complex research that poses 
ethical dilemmas, such as genetic research; 
• lack of mechanisms for quality assurance and avenues 
of redress for researchers; 
• high running costs, especially for project monitoring. 
Some RECs charge for ethical review. To avoid this being 
seen to compromise committee independence, the 
Nuffield Council suggests that fees could be paid into a 
central fund for training and development.7 
 
Box 4. Case study: MalariaGEN 
MalariaGEN is a global research network with 24 units in 20 
countries across Africa, Asia, Europe and North America. It 
is funded mainly by the Gates Foundation and the Wellcome 
Trust. The network brings together expert scientists to 
analyse human genetic variation in susceptibility to malaria. 
The research is co-ordinated from Oxford University and was 
reviewed as a whole by the Oxford Tropical Research Ethics 
Committee. Each unit also applies for ethical clearance for 
particular projects from a local or national REC. MalariaGEN 
faces a number of ethical challenges, including: balancing 
standardisation with sensitivity to the diversity of cultures 
within and between countries; the implications of linking 
genetic data to ethnicity; collecting samples in difficult or 
emergency situations and developing appropriate methods to 
ensure valid consent and community participation. 
The network has established an innovative system for 
dealing with such issues. An ethics team in Oxford supports 
the research units through site visits, ethics training, 
facilitating contact with local bioethics experts and setting 
up exchanges of experience and best practice. It has also 
designed a consent form template and produced guidelines 
on how this can be adapted to local contexts. Field 
researchers have found the team’s support very useful. For 
more information see www.malariagen.net. 
Since around 2000, efforts to improve research ethics in 
developing countries have been expanding. Several 
organisations fund training in ethical review for REC 
members, researchers and other stakeholders (see Box 
5). Ethicists and researchers from the UK and developing 
countries believe international investment has improved 
the availability and quality of ethical review, particularly 
in Africa. Nevertheless, some are concerned that 
international programmes are imposing a Western system 
of ethical review on developing countries and that 
training at a broader level than RECs is needed, among 
institutional authorities and national officials. 
Box 5. Research ethics training programmes 
Initiatives to improve research ethics in developing countries: • The World Health Organisation’s (WHO) Strategic 
Initiative for Developing Capacity in Ethical Review 
supports capacity building based on both local values 
and international standards, including WHO’s 
Operational Guidelines for Ethics Committees. • Fogarty International Center (an international arm of 
the US National Institutes of Health) funds ethics 
courses in and for Africa, Asia and Latin America, 
aimed at professionals from these regions. • The Wellcome Trust sponsors research, studentships, 
travel grants, seminars, pilot projects and other capacity 
building initiatives through its Ethics of Biomedical 
Research in Developing Countries grant schemes. • The Africa Malaria Network Trust’s Health Research 
Ethics Project, funded by the Bill and Melinda Gates 
Foundation, runs training workshops, an online forum 
and an ‘Ask the Expert/Ethicist’ programme. 
 
Ethical review capacity in the UK 
Only three research institutions in the UK have RECs that 
specialise in reviewing proposals for research in 
developing countries: Oxford University, the London 
School of Hygiene and Tropical Medicine and the 
Liverpool School of Tropical Medicine. Some researchers 
believe RECs at other institutions may not have adequate 
knowledge or experience to assess what might be 
appropriate in the developing world. A REC dealing 
primarily with UK-based research, for example, may 
insist on an inappropriate informed consent procedure, or 
expect researchers from countries with sporadic internet 
access to apply for review online. Some UK RECs may be 
asked by external funders like the US National Institutes 
of Health to adjust their procedures and memberships, 
which could have time and cost implications. 
 
The informed consent process 
Obtaining consent for research 
A fundamental principle of research ethics is that a 
participant agreeing to take part in research should do so 
voluntarily and with sufficient knowledge and 
understanding of the procedures, risks and benefits 
involved. This is usually ensured through oral 
consultation and written consent. In clinical trials, the 
International Conference on Harmonisation Guideline for 
Good Clinical Practice is widely followed by both public 
and private sector researchers. This requires very detailed 
consent forms, which may not be feasible where 
potential participants have received no formal education. 
Determining what constitutes free and informed consent 
and the best method of obtaining it can be difficult in 
such circumstances. Explaining a genetic study or a 
randomised trial may be conceptually challenging, for 
example. Some projects use visual aids to give 
information in areas where literacy levels are low. 
 
The International Conference on Harmonisation Guideline 
for Good Clinical Practice is followed widely by both 
public and private sector researchers in clinical trials. 
This requires very detailed consent forms, which may not 
always be feasible. Other forms of research needing 
special consideration of consent procedures include: 
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• those where participants might confuse a research 
intervention with healthcare; 
• profit-making ventures, for which participants must be 
fully informed about potential commercial benefits; 
• genetic studies (that might find variable susceptibility 
to malaria between ethnic groups, for example). 
 
Community engagement and consent 
Engaging the local community in research planning and 
monitoring can help to ensure informed consent is 
obtained in a culturally appropriate manner, as well as 
address other concerns. Ethical guidelines suggest this 
can be done through local leaders, community advisory 
boards (CABs) or similar bodies, the appropriate route 
depending on the particular cultural context. A universal 
standard is that individual consent remains paramount, 
but this can be difficult to guarantee in hierarchical 
societies. Some ethicists and researchers note that, in 
practice, communities are often presented with a 
‘research package’ pre-approved by RECs. Also, some 
scientists equate community engagement with gaining 
permissions from state authorities. Programmes such as 
those supported by DFID (Box 1) try to ensure local 
concerns and needs are addressed through employing 
researchers from host countries, liaising with local 
leaders and CABs and communicating in local dialects. 
Meeting local needs 
RECs usually require a medical research proposal to 
demonstrate that a project will be relevant to local or 
national health needs. This is to ensure that research is 
not exploitative (a concern often levelled at private sector 
research in particular). Considerations include whether 
the research is likely to lead to interventions appropriate 
to the local context (heat-stable drug formulations, for 
example) and in a reasonable timeframe. Some ethicists 
and researchers have questioned the growing focus on 
genetic studies, predicting that these will have few 
concrete outputs in the medium term. They have also 
expressed concern that the focus of some funding 
streams on specific diseases may not correlate with the 
priorities of the communities affected. 
 
Individual and community benefits 
Some benefits are integral to the research process: 
• participants may be offered remuneration for travel 
costs or loss of earnings; 
• diagnostic or treatment services may need to be 
enhanced to enable research to take place; 
• researchers may learn new skills or be provided with 
improved facilities. 
 
Sometimes projects offer benefits that bear little direct 
relation to a given research project. These can be offered 
on an individual or community basis: food for individuals 
or a grain mill for a community, for example. This is a 
sensitive area, as such benefits could be seen as ‘undue 
inducements’ to vulnerable people to participate in 
research,9 thus projects have become nervous about 
offering them. Some researchers in developing countries 
see this as unfair, arguing that it would be unethical not 
to meet the basic needs of those taking part in research. 
 
Long-term benefits 
RECs often scrutinise research proposals to see whether 
benefits will be sustained in the long term. Issues 
include: 
• whether projects will build research capacity in-
country rather than train local researchers overseas; 
• what share participants should have in any profits 
resulting from intellectual property rights attached to 
the products of research; 
• how any improvements in local healthcare provision 
will be maintained once a research project is over; 
• whether participants should have preferential access 
to any new interventions and, if so, for how long. 
 
Healthcare provision is generally seen as the duty of 
governments, although Oxfam argues that profit-seeking 
projects should guarantee participants treatment for as 
long as they need it. There is a concern that shifting this 
duty to companies or funders might dissuade them from 
investing in research, particularly for chronic diseases 
such as HIV/AIDS. The MRC, for example, cannot 
support healthcare provision in another country 
indefinitely. Projects can usually resolve these dilemmas 
by discussing post-trial arrangements fully with 
governments and communities before a project starts; it 
is when this does not happen that difficulties may ensue. 
 
Overview 
• The UK funds biomedical research in developing 
countries from public and private sources. 
• Research Ethics Committees in the UK and developing 
countries conduct ethical review of research proposals, 
but some may lack sufficient resources and expertise.  
• How policies on informed consent, community 
engagement and benefit distribution are put into 
practice varies according to the contexts in which 
research projects are carried out. 
• Funding for research may not match local priorities. 
• Revisions to the Declaration of Helsinki in 2008 may 
have implications for UK policies on research ethics. 
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